Acrivon is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for endometrial cancer, and has received Fast Track designation from the FDA. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368 treatment. The company leverages proprietary biomarker-driven precision medicine to differentiate its approach in competitive oncology markets.
Cyborg Score Rationale
Market Cap is approximately $77M with significant clinical validation (FDA Fast Track designation, Breakthrough Device designation). Recent clinical data demonstrates meaningful efficacy signals, though company remains pre-revenue and faces typical biotech execution risks. Stock volatility (beta 1.77) and recent price pressure reflect early-stage profile.
Top Insights
Phase 2b ACR-368 data show 39% overall response rate with 52% confirmed response rate in serous endometrial cancer, addressing high unmet need in aggressive cancer subtype
AP3 platform generates terabytes of proprietary data using phosphoproteomics to identify drug-regulated pathway activity, enabling rapid actionable insights for precision patient selection
ACR-2316 (WEE1/PKMYT1 inhibitor) in Phase 1 development and CDK11-targeting candidate ACR-6840 in preclinical stage provide pipeline diversification
Trial expanding with European sites expected to begin enrollment in early Q2 2026, targeting completion by end Q3, accelerating path toward potential registration
Named Competitors
Prexasertib (LY2606368) — CHK1/CHK2 inhibitor in development
WEE1 Inhibitors — Cell cycle checkpoint inhibitors in development
Other Precision Oncology Platforms — Biomarker-driven and AI-enabled drug discovery platforms
Recent Developments
(March 2026) ACR-368 Phase 2B data conference highlighting 52% ORR in serous endometrial cancer with key opinion leader panel
(February 2026) Completion and certification of CLIA certified laboratory
(January 2026) Clinical update webcast on ongoing Phase 2B studies and planned Phase 3 trial for ACR-368
Open the full interactive Acrivon Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.